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Background: At present, much of the attention within tuberculosis (TB) management is spent on microbiological
cure, and its impact on health-related quality of life (HRQoL) is either undervalued or seldom considered. The aim
of this study was to evaluate the impact of TB treatment on HRQoL of new smear positive pulmonary tuberculosis
(PTB) patients. Moreover, we also aimed to determine whether the selected socio-demographic and clinical
variables were predictive of variability in the HRQoL scores over time.
Methods: This was a prospective follow-up of new smear positive PTB patients who were diagnosed at the chest
clinic of Penang General Hospital between March 2010 and February 2011. All eligible patients (i.e., a new case of
smear positive PTB, literate and aged 18 years or above) were asked to self-complete the SF-36v2 questionnaire at
the start of their treatment, and then subsequently after the intensive phase and at the end of the treatment. A
score on a health domain or component summary measure that was less than 47 norm-based scoring (NBS) point
was considered indicative of impaired function within that health domain or dimension. Likewise, an individual
having mental component summary (MCS) score ≤ 42 NBS point was considered to be at the risk of depression.
Repeated measures ANOVA test was performed to examine how the summary scores varied over time, and to
determine whether independent variables were predictive of variability in the physical component summary (PCS)
and MCS scores over time.
Results: A total of 216 patients completed the SF-36v2 questionnaire at the start of their treatment. Out of these,
177 and 153 completed the questionnaire at the second and third follow-ups, respectively. The mean PCS scores at
the start of the treatment, after the intensive phase and at the end of treatment were 41.9 (SD 5.1), 45.8 (SD 4.8)
and 46.0 (SD 6.9), respectively. Similarly, the mean MCS scores at the start of the treatment, after the intensive phase
and at the end of the treatment were 39.9 (SD 7.3), 45.0 (SD 6.8) and 46.8 (SD 7.8), respectively. More than 23% of
the patients were at the risk of depression at the end of their TB treatment. Patient’s age and being a smoker were
predictive of differences in the PCS scores. Similarly, monthly income, being a smoker and TB-related symptoms at
the start of the treatment were predictive of differences in the MCS scores.
Conclusion: Although HRQoL improved with the treatment, the scores on component summary measures showed
compromised physical and mental health among study patients even at the end of their TB treatment.
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At present, much of the attention within tuberculosis (TB)
management is spent on microbiological cure, and its im-
pact on health-related quality of life (HRQoL) is either
undervalued or seldom considered [1]. Even, the most re-
cent guidelines on the management of TB are silent on this
critical aspect [2]. Existing literature shows that TB has
substantial and encompassing impact on HRQoL of in-
fected patients. For example, studies showed that as com-
pared with the general population, TB patients reported
deficits in their physical and mental well-being [3-7]. Con-
stitutional TB symptoms especially loss of weight, loss of
appetite, fever, fatigue and body pain can adversely affect
the patient’s role in a society. With regard to pulmonary tu-
berculosis (PTB), the patients usually present themselves
with a history of chest symptoms such as cough (productive
or non-productive), chest pain and hemoptysis. These
PTB-specific symptoms can further limit the patient’s role
in work and social activities. In some communities, TB pa-
tients have to face social rejection and isolation because
they are considered to be a source of infection for the
healthy individuals [1,8,9]. In a few studies, TB patients
themselves reported that they experienced negative emo-
tions such as anxiety and fear [1,8]. Stigmatization and
negative emotions resulting from the illness could result in
a long-term impairment of patient’s psychosocial well-being
[10] which may lead to work absenteeism resulting in loss
of productivity and reduced monthly income [11].
The Patients’ Charter for TB Care allows the patients
to evaluate the program’s performance [2]. From the pa-
tient’s perspective, one of the major performance indica-
tors might be the capability of the National Tuberculosis
Program (NTP) to address the physical and mental well-
being of the patients. Therefore, the assessment of
HRQoL of TB patients as an additional indicator of per-
formance will add value to the NTP.
With regard to the impact of TB treatment on HRQoL,
only two longitudinal studies from Asia are available in
medical literature [11,12], although none used widely ac-
ceptable HRQoL assessment tool. Likewise, published lit-
erature shows that, amongst the TB patients in the
Malaysian population, there is a paucity of research with re-
gard to HRQoL. With these voids in literature, we con-
ducted a longitudinal study to evaluate the impact of TB
treatment on HRQoL of smear positive pulmonary PTB pa-
tients. Moreover, we also aimed to determine whether the
selected socio-demographic and clinical characteristics were
predictive of variability in the HRQoL scores over time.
Methods
Study settings
The study was conducted at the chest clinic of Penang
General Hospital (PGH), which is the first health care fa-
cility in Malaysia since 1961. At present, it is the secondlargest government hospital with a capacity of 1,107
beds, and acts as a point of reference tertiary health care
facility in the Northern Region of Malaysia.
The chest clinic of PGH has three full time chest con-
sultants and a minimum of five to six medical officers.
In addition, the chest clinic has dedicated paramedic
staff committed to providing quality care to the patients.
The chest clinic has well equipped TB diagnostic labora-
tory where the specimens of TB suspects and existing
TB patients are investigated using sputum smear exam-
ination, culture, nucleic acid amplification tests and drug
sensitivity testing. The radiology and pathology depart-
ments of PGH also provide routine investigation services
to TB patients.
The confirmed cases of TB are advised to take their
TB medication either at the chest clinic or at a primary
health care unit. In general, patients are advised to take
their daily medication under the direct observation of
the staff nurse at the chest clinic or a primary health
care unit. However, some patients are allowed weekly
packing of the daily dose. Weekly packing of the daily
dose is only available at the chest clinic. Patients who
continue their daily TB medication at a primary health
care unit are advised to visit the chest clinic (every two
weeks during the intensive phase and every month dur-
ing the continuation phase) for routine investigation. Pa-
tients who default from their treatment for five
consecutive days are traced by a team of staff comprising
a TB-coordinator, a staff nurse and an attendant.Study design and population
This was a prospective follow-up of new smear positive
PTB patient diagnosed at the chest clinic of PGH be-
tween March 2010 and February 2011. The patients
were followed until they completed their TB treatment
(i.e., mid of December 2011).
There are approximately 400 new smear positive PTB
patients registered at the chest clinic of PGH every year.
This number was used as the total population from
which the representative sample was drawn. Using an
accepted margin of error of 5% and a 95% confidence
interval, the minimum sample size was 197 patients.Health related qualify to life assessment questionnaire
and its scoring
Despite the abundance of questionnaires now avail-
able to measure HRQoL in TB patients, the Short
Form-36 (SF-36) health survey remains the most valid
option [3,4,6,10,13,14]. Psychometric evaluations of
the SF-36v2 health survey provide evidence that it is
a reliable and valid tool for detecting differences among
groups defined by socio-demographic status and social
factors [15].
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of HRQoL: physical functioning (PF, 10 items), role-
physical (RP, four items), role-emotion (RE, three items),
bodily pain (BP, two items), vitality (VT, four items), so-
cial functioning (SF, two items), general health (GH, five
items) and mental health (MH, five items). Eight health
domains are further summarized into two; physical com-
ponent summary (PCS) and mental component sum-
mary (MCS) [16,17]. The PF, RP and BP scales strongly
correlate with PCS, while the MH, RE and SF scales
strongly correlate with MCS [17,18]. The GH and VT
scales moderately correlate with physical and mental
components [17]. Studies have demonstrated that com-
pared with eight health domains, the PCS and MCS
scores are easier to interpret and simpler to analyse sta-
tistically [17].
The translations of the SF-36v2 are controlled and
managed by the International Quality of Life Assessment
(IQOLA) project researchers. These translations are
developed using a standard IQOLA translation meth-
odology. This involves multiple independent forward
translations by native speakers, reconciliation of the
translations into one form, backward translation of
this translation into English to check for conceptual
equivalence and small qualitative debriefing tests
[19]. For this study, the final translated questionnaires
(in Malay, Tamil and Mandarin) were the official
translation made available through Quality Metric
Incorporated.
The standard norm-based scoring (NBS) of eight
health domains and summary components were ob-
tained using the standard scoring algorithms (United
States weights). The standard scoring algorithms and the
standard component summary measures were used
based on the recommendations by the developers [17]
and other similar studies from Hong Kong and Malaysia
[18,20,21]. Quality Metric’s QM Certified Scoring Soft-
ware was used for scoring the questionnaires.
Data collection
During the study period, all eligible patients (i.e., a new
case of smear positive PTB, literate and aged ≥ 18 years)
were asked to self-complete the SF-36v2 questionnaire
(either Malay, Mandarin, Tamil or English version) at
the start of the treatment, and subsequently after the in-
tensive phase (IP) (second follow-up) and at the end of
the treatment (third follow-up) [3,6,13,14]. The patients’
socio-demographic, clinical and treatment-related data
were obtained from their medical records and TB notifi-
cation forms.
Patients were excluded from the study if they were
drug abusers or suffering from a major comorbidity
(i.e., human immunodeficiency virus (HIV) co-infection,
rheumatic disease, psychiatric disease, or malignancy) [4,6].When any of the enrolled patients did not visit the
chest clinic (for second and third follow-ups) on the
scheduled clinic hours, attempts were made to trace the
patient at the primary health care unit and/or at a later
visit. Enrolled patients, who were unable to participate
in the study at the second follow-up (e.g., defaulter,
transferred out, or not willing to further participate in
the study), were not asked to complete the questionnaire
at the end of the treatment.
Trained data collectors (three staff nurses at the chest
clinic), in clear and simple language, explained the pur-
pose of the study to all eligible participants, and the pa-
tients who agreed to participate signed an informed
consent form. Throughout the study period, for the data
collection, a comfortable place was allotted in the dir-
ectly observed therapy (DOT) room of the chest clinic.
The patients were assured about the confidentiality of
the data provided. They were also told about their right
to withdraw from the study at any time. Permission to
use the questionnaire was obtained from Quality Metric
Incorporated, Lincoln, U.S.
Statistical analysis
Data were analysed using the PASW (Predictive Analysis
SoftWare, version 19.0. Armonk, NY: IBM Corp.). All
continuous variables were reported as means (SD). Cat-
egorical variables were described using counts and pro-
portions (%). During the treatment, a ≥ 3 NBS point
change in the health domain scales and component
summary measures represented minimal clinically im-
portant difference (MCID) [17,22]. The scores on health
domain scales and component summary measures (PCS
and MCS), ranging from 47 to 53, were considered
equivalent to the general population norms. Similarly, a
score on a health domain scale or component summary
measure that was less than 47 NBS point was considered
indicative of impaired function within that health do-
main or dimension. Likewise, an individual having MCS
score ≤ 42 NBS point was considered to be at the risk of
depression [17]. General linear model (GLM) repeated
measures ANOVA analysis was used to examine how
the component summary scores varied over time, and to
determine whether other variables (independent vari-
ables) were predictive of variability in the PCS and MCS
scores over time. Using the commonly used guidelines,
effect size was ranked small (partial eta squared = .01),
moderate (partial eta squared = .06) and large (partial eta
squared = .14) [23]. The significance of the statistical
tests was taken at a p-value of < 0.05.
Ethical approval
The study was registered at the National Medical Re-
search Register (NMRR), Malaysia. The design and con-
duct of this study was approved by the National Institute
Table 1 Socio-demographic characteristics of the patients
Characteristics Patients n (%)
Sex
Male 147 (68.1)
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(Registration ID: NMRR-10-77-5099; MERC reference:
dim. KKM/NIHSEC/08/08/04P10-69).Female 69 (31.9)

























≤ 1000 76 (35.2)
> 1000 140 (64.8)
*Malaysian Ringgit.Results
The study population included 336 new smear positive
PTB patients. Of these, 216 completed the SF-36v2
questionnaire at the start of their treatment. The
remaining 126 patients were either judged ineligible (i.e.,
illiterate, foreigner, drug abusers, and/or HIV positive)
or unwilling to participate in the study. Out of 216 pa-
tients, 177 and 153 completed the questionnaire at the
end of second and third follow-ups, respectively. Conse-
quently, the overall dropout rate was 29.2%. The drop-
out of the patients during these phases of the treatment
were either due to their refusal to participate further in
the study, or due to their death, default or transfer to
other health care facilities. Table 1 and Table 2 describe
the socio-demographic and clinical characteristics of the
study patients, respectively.
Table 3 describes the NBS of eight health domains at
different stages of the treatment. During the treatment,
with the exception of the RP scale, a change of ≥ 3 NBS
point (representing MICD) was observed for all health
domains. At the baseline and at the end of the IP, the
mean scores for all health domains (except for the VT at
the end of the IP) were less than 47 NBS points. In a
similar fashion, at the end of the treatment, the mean
scores for all health domains (except for the BP and VT)
were less than 47 NBS points.
Table 4 describes the mean PCS and MCS scores for
the study patients. Throughout the treatment, both PCS
and MCS scores were less than the lower cut-off point
of the general population norms. However, during the
treatment, MCID (a change of ≥ 3 NBS point) was ob-
served for both component summary measures. An im-
portant finding of this study was the risk of depression
in 67.1% patients at the start of their TB treatment.
Similarly, 35.0% and 23.5% patients were at the risk of
depression after the IP and end of the treatment,
respectively.
GLM repeated measures ANOVA test was performed
to compare the component summary scores at the start
of the treatment, at the end of the IP and at the end of
the treatment. Table 5 presents the mean scores for the
component summary measures. The analysis revealed a
significant effect for PCS and MCS.
Table 6 describes that patient’s age (F = 3.229, df = 1.731,
223.281) interacted with time to predict trends in the PCS
scores. Similarly, monthly income (F = 3.710, df = 1.726,
222.640) and hypertension (F = 4.430, df = 1.726, 222.640)
interacted with time to predict trends in the MCS scores.Table 7 shows that age ≥ 45 years (F = 9.805, df = 1,
129) and being a smoker (F = 9.664, df = 1, 129) were
predictive of differences in the PCS scores. As the differ-
ences between the groups at time point 2 and 3 were
largely reflective of the differences that existed at base-
line (time 1), it seems that the differences (in the PCS
scores) that existed between groups were more likely to
be attributed to the differences in composition of the
groups (Figures 1 and 2).
Monthly income more than 1000 MYR (F = 10.817, df =
1, 129), being a smoker (F = 7.078, df = 1, 129) and ≥ 3 TB-
related symptoms at the start of the treatment (F = 7.273,
df = 1, 129) were predictive of differences in the MCS
scores (Table 7). As the differences between the groups at
time point 2 and 3 were largely reflective of the differences
Table 2 Clinical characteristics of the patients
Characteristics Patients n (%)
Form of TB
Smear positive PTB* 206 (95.4)
Smear positive PTB* and EPTB† 10 (4.6)
History of cough (weeks)
< 4 59 (27.3)







Number of TB symptoms at the start of treatment
≥ 3 154 (71.3)







*Pulmonary Tuberculosis; †Extrapulmonary Tuberculosis.
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ences (in the MCS scores) that existed between groups
were more likely to be attributed to the differences in com-
position of the groups (Figures 3, 4 and 5).
Discussion
Only a few studies in the literature prospectively studied
TB patients’ HRQoL during the whole treatment periodTable 3 SF 36v2 health domain scores at different stages
of the treatment using norm-based scoring







PF 41.3 (8.1) 45.5 (7.8) 45.5 (8.7)
RP 40.0 (8.1) 43.9 (7.8) 42.7 (7.6)
BP 41.6 (8.3) 46.3 (8.3) 48.5 (8.5)
GH 39.4 (7.9) 44.3 (7.7) 44.3 (10.0)
VT 43.4 (8.2) 50.0 (8.4) 51.8 (9.2)
SF 40.3 (8.5) 43.1 (9.2) 45.2 (8.6)
RE 37.0 (10.6) 41.4 (9.4) 41.9 (9.2)
MH 40.7 (8.8) 46.6 (8.1) 46.8 (7.6)
*Scales: PF (physical functioning), RP (role-physical), BP (bodily pain), GH (general
health), VT (vitality), SF (social functioning), RE (role-emotion), MH (mental health).[6,11,12,24]. Out of these, only two studies were con-
ducted in Asia [11,12]: one used a DR-12 questionnaire
and the other used a modified version of the SF-36
health survey to quantify HRQoL in TB patients. These
findings highlighted the existence of a gap in literature
with regard to a follow-up study using a validated tool to
gauge the impact of TB treatment on HRQoL of smear
positive PTB patients.
In the present study, 216 smear positive TB patients
completed the SF-36v2 questionnaire at the start of the
treatment. Out of these, 153 respondents completed the
questionnaire at the end of the treatment. The study’s
sample size was larger than all above cited follow-up
studies, with the exception of one study which was con-
ducted in India [11]. One of the major reasons for the
higher enrollment rate in above cited Indian study might
be attributed to the higher incidence rate of TB in India.
The findings of our study showed that there were clin-
ically and statistically significant improvement in the
scores on health domain scales (except for the RP) and
summary measures. However, despite these improve-
ments following TB treatment, the mean PCS and MCS
scores, at the end of the treatment, were less than 47
NBS points. This indicated compromised health. Simi-
larly, at the end of the treatment, scores on all health do-
main scales (except for the VT and BP) were less than
47 NBS points. These findings clearly suggested that al-
though TB treatment had significantly improved the pa-
tients’ perception about their health, altered HRQoL
continued even after the completion of the treatment.
Similar to current study’s findings, Marra and associates
reported that compared with the U.S. general population
norms, patients with active TB had worse scores on the
SF-36 scales at the end of the treatment [6]. A few other
studies also reported almost similar findings [3,10].
With regard to HRQoL at the start of the treatment,
the scores on health domain scales and summary mea-
sures were less than 47 NBS points. The RE and GH
scales were the most affected health domains which
meant that the patients had severe problems in perform-
ing their daily life activities due to emotional stress.
Similarly, it also suggested that the patients rated their
overall health as poor, and even expected it to get worse
[17]. At the start of the treatment, compared with PCS,
lower MCS scores showed that the patients experienced
more psychological distress and role limitation due to
emotional problems than the physical problems [17]. In
line with the current study’s findings, a study from
Canada also reported lower HRQoL scores on SF-36
health domain scales and component summary mea-
sures. The Canadian study also reported that, at the start
of the treatment, the RE and RP were among the most
affected health domains [6]. Likewise, a study from the
United Kingdom (UK) reported compromised HRQoL
Table 4 Changes in the mean summary scores: minimal clinically important difference estimates
Summary
measures*
Mean scores (SD) Mean change
in scores†Start of treatment End of intensive phase End of treatment
PCS 41.9 (5.1) 45.8 (4.8) 46.0 (6.9) 4.1
MCS 39.9 (7.3) 45.0 (6.8) 46.8 (7.8) 6.9
*Summary measures: PCS (physical component summary), MCS (mental component summary); †Mean change in summary scores from start to end of
tuberculosis treatment.
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mary measures [13]. However, contrary to the findings
of our study, earlier studies [6,13] showed that, at the
start of the treatment, physical health was more affected
than the mental health.
With regard to HRQoL scores at the end of the IP, the
findings of this study showed that, except for the SF, a
change of ≥ 3 NBS point was observed for all health do-
main scales and summary measures. These findings
showed that, although HRQoL scores were less than the
general population norms (except for the VT); TB treat-
ment had significantly improved HRQoL of the patients.
A similar trend in the improvement of HRQoL scores in
association with TB treatment was reported elsewhere
[13,24]. Contrary to this, a study from China showed
that, at the end of the IP, the mean RE, BP and SF scores
were not different from those of the controls [3]. The
differences in patients’ HRQoL levels among these stud-
ies might be either due to inconsistency in patients’ char-
acteristics, differences in cultures and mode of data
collection related to HRQoL, or attributable to variation
in the NTP’s performance. With respect to patients’
HRQoL at the end of TB treatment, the findings of the
current study were in accordance with most of the earl-
ier studies in the same area [3,6,14,24].
Our study findings also showed that, at the start of the
treatment, more than 67% patients were at the risk of
depression (MCS score ≤ 42 NBS point). Although, pro-
portion of the patients with the risk of depression de-
creased with the TB treatment, 23.5% patients were stillTable 5 Changes in the mean summary scores: repeated
measures ANOVA analysis
Summary measures* Stages N Mean scores (SD)
Start of treatment 153 42.3 (4.8)
PCS† End of intensive phase 153 45.7 (4.3)
End of treatment 153 46.0 (6.9)
Start of treatment 153 39.8 (7.4)
MCS‡ End of intensive phase 153 44.6 (6.7)
End of treatment 153 46.8 (7.8)
*Summary measures: PCS (physical component summary), MCS (mental
component summary); †Wilk’s Lambda = .62, F (2, 151) = 46.33, p < 0.0005,
multivariate partial eta squared = .38; ‡Wilk’s Lambda = .60, F (2, 151) = 49.51,
p < 0.0005, multivariate partial eta squared = .40.at the risk of depression after the completion of their
treatment. Similar to this study’s findings, a UK study re-
ported high level of depression and anxiety among the
patients at the time when they were diagnosed with TB.
However, depression levels among the patients returned
to normal during TB treatment. This was possibly be-
cause the clinicians in the UK were aware of non-
medical aspects of the disease [13]. However, the risk of
depression in approximately 24% patients indicated that
the clinicians and NTP managers in current clinical set-
ting had underappreciated the TB’s impact on the men-
tal health of TB patients. In a similar fashion, qualitative
studies from Canada and the U.S. showed that, owing to
curable nature of the disease, the clinicians underesti-
mated the impact which TB had on the patients’ HRQoL
[1,8].
In this study, patient’s age and being a smoker were
predictive of differences in the overall PCS scores
(Table 7). Figure 1 demonstrates that compared with the
patients aged less than 45 years, the mean PCS scores
for the patients who were ≥ 45 years of age were lowest
at every time point. Similarly, Figure 2 demonstrates that
compared with the smokers, the mean PCS scores for
the non-smokers were highest at every time point. These
findings demonstrated that the differences between the
groups at time point 2 and 3 were largely reflective of
the differences that existed at baseline (time 1), rather
than the varying impact of TB treatment. A higher prob-
ability of lower PCS scores in elderly patients might be
associated with their old age and the expected decline in
physical health with increasing age [17,25,26]. Similar to
the findings of our study, a Chinese study reported com-
parable association between age and HRQoL scores [3].
Along the same lines, a study from Canada also reported
lower PCS scores in elderly TB patients [6]. Contrary to
our findings, an Indian study showed that literacy, being
employed and absence of TB symptoms at the end of
the treatment were associated with higher PCS scores in
TB patients [14].
With respect to mental health, monthly income, being
a smoker and number of TB-related symptoms at the
start of TB treatment were predictive of the overall MCS
scores. Figure 3 demonstrates that compared with the
patients having monthly income more than 1000 MYR,
the mean MCS scores for those earning ≤ 1000 MYR per
Table 6 Test of within-subjects effects for the summary scores: general linear model repeated measures
ANOVA analysis
Source df F p-value Partial eta squared
Measure: physical component summary*
Time* Age≥ 45 years 1.731 3.229 0.049 .024
Time* Unemployment 1.731 .106 0.873 .001
Time* Monthly income > 1000 MYR 1.731 2.163 0.125 .016
Time* Diabetes 1.731 .108 0.871 .001
Time* Hypertension 1.731 1.225 0.292 .009
Time* Smoker 1.731 .481 0.592 .004
Time* Productive cough 1.731 1.189 0.302 .009
Time*≥ 3 TB symptoms at the start of the treatment 1.731 1.930 0.154 .015
Error 223.281
Measure: mental component summary*
Time* Age≥ 45 years 1.726 .377 0.655 .003
Time* Unemployment 1.726 .615 0.519 .005
Time* Monthly income > 1000 MYR 1.726 3.710 0.032 .028
Time* Diabetes 1.726 .630 0.511 .005
Time* Hypertension 1.726 4.430 0.017 .033
Time* Smoker 1.726 1.106 0.326 .009
Time* Productive cough 1.726 .759 0.452 .006
Time*≥ 3 TB symptoms at the start of the treatment 1.726 1.804 0.172 .014
Error 222.640
*Greenhouse-Geisser values as sphericity cannot be assumed (p < 0.0005).
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non-smokers and the patients with less than three TB-
related symptoms at the start of treatment had higher
MCS scores at every time point compared with the
smokers and those exhibiting ≥ 3 TB-related symptoms,
respectively (Figures 4 and 5). These findings were simi-
lar to the findings of studies from Canada and India
[6,14]. However, a study from China did not find any as-
sociation between smoking and MCS scores [3].
Smoking is known to adversely affect the immune sys-
tem, and can render the smokers more susceptible to in-
fections. Similarly, smokers tend to have higher bacillary
loads because of compromised immune system. A higher
bacillary load can augment the severity of disease which
may adversely affect the patients’ perception about their
mental and physical health [27].
It is a known fact that people with higher monthly in-
come face low economic hardships. Consequently, com-
pared with the persons falling in the low socio-economic
category, they are expected to have better mental satis-
faction [28]. In the present study, better MCS scores
among the patients with higher monthly income added
weight to this argument. Higher MCS scores among pa-
tients with higher income were also reported in other
studies [25,26].Limitations
The findings of our study need to be interpreted in the
light of certain limitations:
i. The study only included smear positive PTB
patients. Therefore, the study’s results could
not be generalized for all types of TB patients.
However, from the public health perspective,
smear positive PTB patients are the most
important group of TB patients and these
are the most common group of patients used
to evaluate the NTP’s performance.
ii. With regard to HRQoL assessment, patients’
dropouts were observed at the second and third
follow-ups. Indeed, this is the limitation inherent
in the longitudinal study design. To reduce this
study bias, attempts were made to contact the
patients at the primary health care units and/or
at a later visit, if patients under study were not
traceable on the scheduled clinic hours (for
second and third follow-ups). Of course one
might also think that the patients who dropped
out at the second and third follow-ups might
have a worse clinical condition which could
affect the study’s findings. Nevertheless, medical
Table 7 Test of between-subjects effects for the summary scores: general linear model repeated measures
ANOVA analysis
Source df F p-value Partial eta squared
Measure: physical component summary
Age≥ 45 years 1 9.805 0.002 .071
Unemployment 1 .252 0.617 .002
Monthly income > 1000 MYR 1 3.019 0.085 .023
Diabetes 1 1.767 0.186 .014
Hypertension 1 .003 0.956 .000
Smoker 1 9.664 0.002 .070
Productive cough 1 3.271 0.073 .025
≥ 3 TB symptoms at the start of the treatment 1 2.799 0.097 .021
Error 129
Measure: mental component summary
Age≥ 45 years 1 .002 0.968 .000
Unemployment 1 .058 0.810 .000
Monthly income > 1000 MYR 1 10.817 0.001 .077
Diabetes 1 .057 0.811 .000
Hypertension 1 1.726 0.191 .013
Smoker 1 7.078 0.009 .052
Productive cough 1 3.748 0.055 .028
≥ 3 TB symptoms at the start of the treatment 1 7.273 0.008 .053
Error 129
Figure 1 Age more than or equal to 45 years: differences in estimated marginal means of physical component summary.
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Figure 2 Being a smoker: differences in estimated marginal means of physical component summary.
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http://www.hqlo.com/content/12/1/19records of the non-responders (except six
patients at the second follow-up) did not show
any evidence that might have limited their
further participation in this study due to
worse clinical condition.Figure 3 Monthly income more than 1000 MYR: differences in estimateiii. As we used the self-administered version of SF-
36v2 health survey, illiterate smear positive PTB
patients were unable to participate in the study.
Therefore, our findings should be applied with
caution to illiterate PTB patients.d marginal means of mental component summary.
Figure 4 Being a smoker: differences in estimated marginal means of mental component summary.
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http://www.hqlo.com/content/12/1/19Conclusion
The study’s findings showed that, after the treat-
ment, there were clinically and statistically significant
improvements of HRQoL (as measured by SF-36v2) for
the TB patients. However, the mean PCS and MCS
scores at the end of the treatment were still less than 47
NBS points.Figure 5 Three or more tuberculosis symptoms at the start of the tre
component summary.Diminished HRQoL scores among the patients, even
at their treatment completion, call upon the urgent at-
tention of NTP managers to collect the patient-reported
outcomes data at various stages of the treatment. This
strategy will enable the clinicians to take timely actions
for addressing physical and/or mental well-being of the
patients.atment: differences in estimated marginal means of mental
Atif et al. Health and Quality of Life Outcomes 2014, 12:19 Page 11 of 11
http://www.hqlo.com/content/12/1/19The clinicians should also pay special attention to the
identified risk factors for poor HRQoL in TB patients.
Doubtless, this could bring about comprehensive client-
oriented improvements in the NTP.
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